

REVIEW ARTICLE

## Inhibitory effect of silver nano-particles on multidrug resistant *Staphylococcus aureus*: a review

Yasir Ali Yasir<sup>1\*</sup>, Muhammad Aamir<sup>2</sup>, Kanwal Akhtar<sup>3</sup>, and Moosa Raza<sup>4</sup>

<sup>1</sup>Faculty of Veterinary Science, Bahauddin Zakariya University, Multan, Pakistan

<sup>2</sup>Department of Pharmacology, Islam Medical College Sialkot, Pakistan

<sup>3</sup>Department of Physics, Government College women university, Faisalabad

<sup>4</sup>Department of Pharmaceutics, University of Lahore, Pakistan

### Abstract

Nanotechnology is an emerging science involving the utilization of nanoparticles. Silver nanoparticles are relatively safer to use because they exhibit no toxicity to the host cell as well as these particles are also able to treat inflammatory conditions and have better results than steroids. Silver nanoparticles can be used to treat the various diseases originating from *Staphylococcus aureus* (stomatitis, mental illness, epilepsy, nicotine addiction and gastroenteritis). *Staphylococcus aureus* is a gram-positive bacterium that is extremely harmful pathogen both for animals and human being. *S. aureus* is highly lethal that infects multiple systems of the body including blood, lungs and skin. *S. aureus* has a very high tendency to develop antibiotic resistance. This resistance is plasmid mediated. Therefore, to counteract this property, the role of silver nanoparticles (AgNPs) were evaluated. After performing multiple experiments, it was observed that AgNPs were highly effective against multidrug resistant *S. aureus*. These evaluations were conducted by observing inhibition zone using different shape, size and concentrations of AgNPs. Best results were obtained by using spherical shape, 2-5 nm AgNPs. An inhibition zone of 53.9% was achieved as compared to hexagonal and pentagonal having larger size 50-100 nm that exhibited 42.8 % inhibition zone. It means that small sized AgNPs have more potential to produce antibacterial activity against *S. aureus* as compared to available antibiotic groups. AgNPs are getting more attention in scientific community due to their broad-spectrum range in medical applications and for their uses in food products. On the basis of previous findings, it's worth mentioning that AgNPs exhibit strong antibacterial activity and can be utilized as an alternative of antibiotics.

### Keywords

Antibiotics  
Multidrug  
resistance  
Silver  
nanoparticles  
*Staphylococcus  
aureus*

**To Cite This Article:** Yasir YA, Aamir M, Akhtar K and Raza M, 2020. Inhibitory effect of silver nano-particles on multidrug resistance *Staphylococcus aureus*: a review. *J Toxicol Pharmaceut Sci*, **4(1-2)**, 1-6.

### Introduction

Nanotechnology is a developing field of science which involves the development of nanoparticles for various applications due to their volume to surface properties (Nanda & Saravanan, 2009). Silver nanoparticles (AgNPs) are usually lesser than 100 nm having 20-15000 atoms (Chen & Schluesener, 2008). Nanoparticles are famous for their antimicrobial activity

(Choi & Hu, 2008; Taglietti et al., 2014). Historically, silver particles have been used widely for many purposes. Silver particles used as ornaments and jewelry. Silver jewelry, wares and ornaments were considered as beneficial for their health (Salata, 2004; Kim et al., 2007; Shahverdi et al., 2007; Lara et al., 2010). Silver salts are used to treat various diseases such as mental illness, nicotine addiction, epilepsy, stomatitis and gastroenteritis (Alidaee et al., 2005; Amin et al., 2007).

\*Corresponding author: Email: dryasir2613@gmail.com

AgNPs treated cloths are helpful to minimize the hospital infections originating from *Staphylococcus aureus* (Durán et al., 2007).

*S. aureus* is a gram-positive bacterium and the most frequent pathogen present in joint and bone infections (Sendi et al., 2011; Corrado et al., 2016; Kavanagh et al., 2018). *S. aureus* is present everywhere in soft tissues, blood and urinary tract infections (Arrecubieta et al., 2006; McCaig et al., 2006; Besier et al., 2007; Corey, 2009). Main concern is infection of prosthetic joint leading to failure of joint substitute surgery in which infection of hip joint is most common. However, an elevating level of multiple resistance of drug pathogen has presented and is causing high rates of failure in ongoing treatment (Campoccia et al., 2006). AgNPs have got attention due to their broad spectrum antibacterial and long term activity (Kim et al., 2007). Nowadays, AgNPs are used as additive in biocide in many areas including textiles, machines, washings and toothpaste (Prabhu & Poulouse, 2012; Vance et al., 2015). For medical applications, about 75% of AgNPs are used in nano-enabled products (Yohan & Chithrani, 2014).

Nanoparticles of silver release ions which react with water to produce reactive oxygen species (ROS). These species enter in the cell membrane leading to cell damage which ultimately results in cell death (Chudobova et al., 2013). Recently, it has been reported that antibacterial potential of AgNPs is due to the generation of free radicals (Kim et al., 2007). It has been observed that the most frequent *S. aureus* infections in the hospitals are infective endocarditis, urinary tract infections, impetigo, bacteremia, pneumonia and cellulites (Tong et al., 2015). The harmful effects of *S. aureus* are able to contribute two important factors. One is the plasmids and staphylococcal cassette chromosome mec (SCC Mec) (Méric et al., 2015). Plasmids are the extra chromosomal part of DNA that initiate resistance in multiple *S. aureus* clones (Shearer et al., 2011). Second is the virulence factor of *S. aureus* having wide spectrum that initiate pneumonia and endocarditic like problems (Baran-Raunstrup et al., 1998). AgNPs are one-dimensional, small sized (1-100 nm), wide spectrum anti-bacterial, anti-viral and having anti-fungal activities (Chernousova & Epple, 2013). AgNPs bind with plasma membrane causing the destabilization of plasma membrane that ultimately results in leakage of proton (Gogoi et al., 2006). AgNPs treated cloths are helpful to minimize the hospital infections originating from *S. aureus* (Durán et al., 2007). Figure 1 showed cellular lysis *S. aureus* by generating reactive oxygen species using AgNPs.

**Antibacterial effect of AgNPs:** The antibacterial effect of silver nanoparticles is size dependent. Size of 1-10 nm have been shown to exert direct interaction with cell surface and bacteria (Morones et al., 2005). Later on further studies have shown the effect of silver nanoparticles against staphylococcus cell wall

peptidoglycan especially decomposing the peptide part. Glycan consist of N-Acetyl muramic acid and N-Acetyl glucosamine. Silver nanoparticles attach and destroy these bonds and ultimately leading to the release of muramic acid. As a consequence of which pit formation occurred on cell membrane (Mirzajani et al., 2011).

Previous findings have shown the antibacterial effect of silver nanoparticles having diameter ranges from 2.90-11.25 by stabilizing in chitosan and gelatin polymeric matrix. This study was done to check the effects of silver nanoparticles against *Staphylococcus aureus* by using disc diffusion method. They found that silver nanoparticles were showing inhibition zone of 9.9 nm in *Staphylococcus aureus* (Krishna & Miller, 2012). Further studies have shown the different concentrations of silver nitrate against *staphylococcus aureus* infections after burns. At the lowest 0.5% solution of silver nitrate was effectively used against bacteria in laboratory on broth and agar and on burns in vivo. When dressing was moistened with this solution, the grafts were taken more easily. This AgNO<sub>3</sub> solution also has no toxic effect on developing epidermal cells. So they found that AgNO<sub>3</sub> was effective against *staphylococcus aureus* infections resulting from burns (Bader, 1966).

Many researchers conducted the experiments that hydro gels having high moisture contents when prepared in combination with AgNO<sub>3</sub>, exert promising toxic effects on *S. aureus*. AgNO<sub>3</sub> is also used in creams to treat the inflammatory conditions such as contact dermatitis, atopic dermatitis and psoriasis. AgNO<sub>3</sub> is more efficient in comparison with steroids to treat such conditions. It has no cytotoxicity, resistance and reduce erythema after 1 day treatment (Bhol et al., 2004). Further studies revealed that cell division is restricted in initial stages in *S. aureus* when its contact with AgNO<sub>3</sub> and produced morphological alterations, ultimately resulted in cell lysis (Jung et al., 2008). Alkawareek et al. (2019) have performed experiments to check the antibacterial effects of silver nanoparticles against *S. aureus*. The bacteria was treated with 1 mM AgNP for 1 hour exposure time and resulted in bacteriostatic effect in *S. aureus*. Further experiments were done to evaluate the antimicrobial effect of staphylococcus aureus at different concentrations by using Agar well diffusion method. Figure 2 showed inhibition zone against *S. aureus* at different AgNO<sub>3</sub> concentrations.

Nanda & Saravanan (2009) have reported that synthesized silver nanoparticles using *S. aureus* supernatant to decrease silver ions aqueous solution. These biogenic AgNP showed outstanding antibacterial effects against *S. aureus*. It has been concluded that silver nanoparticles are more efficient than antimicrobial agents. The antimicrobial potentials of AgNP were checked by disk diffusion method at different concentrations. Increasing the concentrations of AgNPs resulted in increasing the inhibitory effects on *S. aureus* as shown in Figure 3.




Figure 1. A schematic diagram of AgNPs generating reactive oxygen species in *S. aureus* (adapted from Moritz & Geszke-Moritz, 2013)




Figure 2. Inhibition zone against *S. aureus* at different AgNO<sub>3</sub> concentrations (adapted from Kim et al., 2011).




Figure 3. Inhibitory effects of AgNPs against *S. aureus* at different concentrations (adapted from Suganya et al., 2015).

Zia et al. (2018) have reported that exact mechanism of silver nanoparticles against *S. aureus* is still not clear due to presence of double layer peptidoglycan. The other mechanism involves the generation of free radicals by which silver particles kill the bacteria. This reaction takes place at the surface of AgNPs when it is in contact with moisture. During this process, there is production of




Figure 4. Different AgNPs concentrations showing different inhibitory zones against *S. aureus*. (adapted from Saravanan et al., 2014).




Figure 5. Percent efficacy of AgNPs against *S. aureus* at different concentrations (adapted from Sung & Lee, 2008).




Figure 6. Inhibition zone at two different AgNPs concentrations (adapted from Suganya et al., 2015).

ROS that leads to damage of the outer bacterial membrane, ultimately resulting in bacterial death (Zia et al., 2018). Further studies had reported the effects of AgNPs against multi drug resistance *S. aureus* at different concentrations by using well diffusion method (Figure 4).

Further findings suggested that AgNPs have been used for better treatment to kill extracellular bacteria. AgNPs having 40 nm size have strong antibacterial

potential to kill *S. aureus* at low concentration of 56  $\mu\text{M}$ . AgNPs size played an important role to inhibit bacterial activity. The size of 100 nm at high concentration of 927 micro M was able to completely restrict the bacterial activity (Liu et al., 2010; Sarkar et al., 2015). Further experiments were performed to check the efficacy of silver impregnated cotton fabrics against *S. aureus* at different concentrations. As the concentrations were increasing, there was increase in efficacy of silver particles (Figure 5).

Further studies suggested that bio AgNPs have the ability to inhibit *S. aureus* and also to kill pathogenic microorganisms. They observed that silver nanoparticles showed minimum inhibitory concentration of 6.25  $\mu\text{g/ml}$  against *S. aureus*. Both bactericidal and bacteriostatic effects of AgNPs were seen against *S. aureus* (Mukherjee et al., 2001). Biological nanoparticles have better combination with pathogens due to their distinguishing characters such as large volume to surface rates (Xiu et al., 2012). The activity of AgNPs was checked against *S. aureus*. Colony forming units were treated with different AgNPs concentrations (20, 60 and 100  $\mu\text{g/mL}$ ). After the treatment, there was a significant reduction in the *S. aureus* colonies. The bactericidal potential of AgNPs increased with increasing the concentrations (Mitra & Das, 2008). Further researchers conducted the experiments at different silver nanoparticles concentrations that exhibited different zones of inhibition in *S. aureus*. This evidence suggested that there is increase in inhibition zone by increasing the AgNPs concentrations (Figure 6).

Kasithevar et al. (2017) conducted the experiments that silver nanoparticles had been synthesized by using extract of CRCP leaves. The developed AgNPs were tested against *S. aureus* isolated from the infections, originated from post-surgery. The AgNPs were highly effective against *S. aureus* and their antimicrobial potential increased with increasing AgNPs concentrations. Kumari et al. (2017) further checked the shape and size dependent antimicrobial potential of AgNPs.

**Conclusion:** Silver particles have strong antimicrobial potential and can be used as an alternative of antibiotics due to their broad-spectrum nature. Due to their smaller size, these nanoparticles can easily penetrate the bacterial membrane. These particles have better compatibility to inhibit the multidrug resistance *S. aureus* and also to treat the various diseases originating from this bacterium. Size and shape of AgNPs play a vital role in the inhibition of multi drug resistance *S. aureus*. Previous findings suggested that smaller the size of silver particles, greater will be the inhibition zone in *S. aureus*. Spherical shaped and small sized silver nanoparticles exhibit maximum inhibition zone. These particles have better combination with pathogens due to their smaller size. So, it is concluded from all previous

findings that AgNPs could be used as powerful weapon against multi drug resistant *S. aureus* and has future perspective against microorganisms.

## References

- Alidaee M, Taheri A, Mansoori P and Ghodsi S 2005. Silver nitrate cautery in aphthous stomatitis: a randomized controlled trial. *British Journal of Dermatology*, 153, 521-525.
- Alkawareek MY, Bahloul A, Abulateefeh SR and Alkilany AM 2019. Synergistic antibacterial activity of silver nanoparticles and hydrogen peroxide. *PloS one*, 14, e0220575.
- Amin M, Glynn F, Phelan S, Sheahan P, Crotty P and McShane D 2007. Silver nitrate cauterisation, does concentration matter? *Clinical otolaryngology: official journal of ENT-UK; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery*, 32, 197-199.
- Arrecubieta C, Asai T, Bayern M, Loughman A, Fitzgerald JR, Shelton CE, Baron HM, Dang NC, Deng MC and Naka Y 2006. The Role of *Staphylococcus aureus* Adhesins in the Pathogenesis of Ventricular Assist Device-Related Infections. *The Journal of infectious diseases*, 193, 1109-1119.
- Bader KF 1966. Organ deposition of silver following silver nitrate therapy of burns. *Plastic and reconstructive surgery*, 37, 550-551.
- Baran-Raunstrup K, Miedzobrodzki J and Ternowitz T 1998. Characteristics of *Staphylococcus aureus* isolates from atopic dermatitis with reference to proteolytic activity. *Acta Microbiologica Polonica*, 47, 167-175.
- Besier S, Smaczny C, von Mallinckrodt C, Krahl A, Ackermann H, Brade V and Wichelhaus TA 2007. Prevalence and clinical significance of *Staphylococcus aureus* small-colony variants in cystic fibrosis lung disease. *Journal of clinical microbiology*, 45, 168-172.
- Bhol K, Alroy J and Schechter P 2004. Anti-inflammatory effect of topical nanocrystalline silver cream on allergic contact dermatitis in a guinea pig model. *Clinical and Experimental Dermatology: Experimental dermatology*, 29, 282-287.
- Camposcia D, Montanaro L and Arciola CR 2006. The significance of infection related to orthopedic devices and issues of antibiotic resistance. *Biomaterials*, 27, 2331-2339.
- Chen X and Schluesener HJ 2008. Nanosilver: a nanoparticle in medical application. *Toxicology letters*, 176, 1-12.
- Chernousova S and Epple M 2013. Silver as antibacterial agent: ion, nanoparticle, and metal. *Angewandte Chemie International Edition*, 52, 1636-1653.

- Choi O and Hu Z 2008. Size dependent and reactive oxygen species related nanosilver toxicity to nitrifying bacteria. *Environmental science & technology*, 42, 4583-4588.
- Chudobova D, Maskova D, Nejdil L, Kopel P, Rodrigo MM, Adam V and Kizek R 2013. The effect of silver ions and silver nanoparticles on *Staphylococcus aureus*. *Microb. Pathog. Strateg. Combat. Sci. Technol. Educ*, 1, 728-735.
- Corey GR 2009. *Staphylococcus aureus* bloodstream infections: definitions and treatment. *Clinical Infectious Diseases*, 48, S254-S259.
- Corrado A, Donato P, Maccari S, Cecchi R, Spadafina T, Arcidiacono L, Tavarini S, Sammiceli C, Laera D and Manetti AGO 2016. *Staphylococcus aureus*-dependent septic arthritis in murine knee joints: local immune response and beneficial effects of vaccination. *Scientific Reports*, 6, 1-16.
- Durán N, Marcato PD, De Souza GI, Alves OL and Esposito E 2007. Antibacterial effect of silver nanoparticles produced by fungal process on textile fabrics and their effluent treatment. *Journal of biomedical nanotechnology*, 3, 203-208.
- Gogoi SK, Gopinath P, Paul A, Ramesh A, Ghosh SS and Chattopadhyay A 2006. Green fluorescent protein-expressing *Escherichia coli* as a model system for investigating the antimicrobial activities of silver nanoparticles. *Langmuir*, 22, 9322-9328.
- Jung WK, Koo HC, Kim KW, Shin S, Kim SH and Park YH 2008. Antibacterial activity and mechanism of action of the silver ion in *Staphylococcus aureus* and *Escherichia coli*. *Applied and Environmental Microbiology*, 74, 2171-2178.
- Kasithevar M, Periakaruppan P, Muthupandian S and Mohan M 2017. Antibacterial efficacy of silver nanoparticles against multi-drug resistant clinical isolates from post-surgical wound infections. *Microbial Pathogenesis*, 107, 327-334.
- Kavanagh N, Ryan EJ, Widaa A, Sexton G, Fennell J, O'Rourke S, Cahill KC, Kearney CJ, O'Brien FJ and Kerrigan SW 2018. *Staphylococcal osteomyelitis*: disease progression, treatment challenges, and future directions. *Clinical microbiology reviews*, 31.
- Kim JS, Kuk E, Yu KN, Kim J-H, Park SJ, Lee HJ, Kim SH, Park YK, Park YH and Hwang C-Y 2007. Antimicrobial effects of silver nanoparticles. *Nanomedicine: Nanotechnology, Biology and Medicine*, 3, 95-101.
- Kim S-H, Lee H-S, Ryu D-S, Choi S-J and Lee D-S 2011. Antibacterial activity of silver-nanoparticles against *Staphylococcus aureus* and *Escherichia coli*. *Microbiology and Biotechnology Letters*, 39, 77-85.
- Krishna S and Miller LS 2012. Host-pathogen interactions between the skin and *Staphylococcus aureus*. *Current Opinion in Microbiology*, 15, 28-35.
- Kumari M, Pandey S, Giri VP, Bhattacharya A, Shukla R, Mishra A and Nautiyal C 2017. Tailoring shape and size of biogenic silver nanoparticles to enhance antimicrobial efficacy against MDR bacteria. *Microbial Pathogenesis*, 105, 346-355.
- Lara HH, Ayala-Núñez NV, Turrent LdCI and Padilla CR 2010. Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria. *World Journal of Microbiology and Biotechnology*, 26, 615-621.
- Liu J, Sonshine DA, Shervani S and Hurt RH 2010. Controlled release of biologically active silver from nanosilver surfaces. *ACS nano*, 4, 6903-6913.
- McCaug LF, McDonald LC, Mandal S and Jernigan DB 2006. *Staphylococcus aureus*-associated skin and soft tissue infections in ambulatory care. *Emerging infectious diseases*, 12, 1715.
- Méric G, Miragaia M, de Been M, Yahara K, Pascoe B, Mageiros L, Mikhail J, Harris LG, Wilkinson TS and Rolo J 2015. Ecological overlap and horizontal gene transfer in *Staphylococcus aureus* and *Staphylococcus epidermidis*. *Genome biology and evolution*, 7, 1313-1328.
- Mirzajani F, Ghassempour A, Aliahmadi A and Esmaeili MA 2011. Antibacterial effect of silver nanoparticles on *Staphylococcus aureus*. *Research in microbiology*, 162, 542-549.
- Mitra RN and Das PK 2008. In situ preparation of gold nanoparticles of varying shape in molecular hydrogel of peptide amphiphiles. *The Journal of Physical Chemistry C*, 112, 8159-8166.
- Moritz M and Geszke-Moritz M 2013. The newest achievements in synthesis, immobilization and practical applications of antibacterial nanoparticles. *Chemical Engineering Journal*, 228, 596-613.
- Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Ramírez JT and Yacaman MJ 2005. The bactericidal effect of silver nanoparticles. *Nanotechnology*, 16, 2346.
- Mukherjee P, Ahmad A, Mandal D, Senapati S, Sainkar SR, Khan MI, Parishcha R, Ajaykumar P, Alam M and Kumar R 2001. Fungus-mediated synthesis of silver nanoparticles and their immobilization in the mycelial matrix: a novel biological approach to nanoparticle synthesis. *Nano Letters*, 1, 515-519.
- Nanda A and Saravanan M 2009. Biosynthesis of silver nanoparticles from *Staphylococcus aureus* and its antimicrobial activity against MRSA and MRSE. *Nanomedicine: Nanotechnology, Biology and Medicine*, 5, 452-456.
- Prabhu S and Poulouse EK 2012. Silver nanoparticles: mechanism of antimicrobial action, synthesis, medical applications, and toxicity effects. *International nano letters*, 2, 1-10.
- Salata OV 2004. Applications of nanoparticles in biology and medicine. *Journal of nanobiotechnology*, 2, 1-6.

- Saravanan M, Jacob V, Arockiaraj J and Prakash P 2014. Extracellular biosynthesis, characterization and antibacterial activity of silver nanoparticles synthesized by *Bacillus subtilis* (NCIM—2266). *Journal of Bionanoscience*, 8, 21-27.
- Sarkar S, Leo BF, Carranza C, Chen S, Rivas-Santiago C, Porter AE, Ryan MP, Gow A, Chung KF and Tetley TD 2015. Modulation of human macrophage responses to *Mycobacterium tuberculosis* by silver nanoparticles of different size and surface modification. *PloS one*, 10, e0143077.
- Sendi P, Banderet F, Graber P and Zimmerli W 2011. Periprosthetic joint infection following *Staphylococcus aureus* bacteremia. *Journal of Infection*, 63, 17-22.
- Shahverdi AR, Fakhimi A, Shahverdi HR and Minaian S 2007. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against *Staphylococcus aureus* and *Escherichia coli*. *Nanomedicine: Nanotechnology, Biology and Medicine*, 3, 168-171.
- Shearer JE, Wireman J, Hostetler J, Forberger H, Borman J, Gill J, Sanchez S, Mankin A, LaMarre J and Lindsay JA 2011. Major families of multiresistant plasmids from geographically and epidemiologically diverse staphylococci. *G3: Genes| Genomes| Genetics*, 1, 581-591.
- Suganya KU, Govindaraju K, Kumar VG, Dhas TS, Karthick V, Singaravelu G and Elanchezhian M 2015. Size controlled biogenic silver nanoparticles as antibacterial agent against isolates from HIV infected patients. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, 144, 266-272.
- Sung WS and Lee DG 2008. The combination effect of Korean red ginseng saponins with kanamycin and cefotaxime against methicillin-resistant *Staphylococcus aureus*. *Biological and Pharmaceutical Bulletin*, 31, 1614-1617.
- Taglietti A, Arciola CR, D'Agostino A, Dacarro G, Montanaro L, Campoccia D, Cucca L, Vercellino M, Poggi A and Pallavicini P 2014. Antibiofilm activity of a monolayer of silver nanoparticles anchored to an amino-silanized glass surface. *Biomaterials*, 35, 1779-1788.
- Tong SY, Davis JS, Eichenberger E, Holland TL and Fowler VG 2015. *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clinical microbiology reviews*, 28, 603-661.
- Vance ME, Kuiken T, Vejerano EP, McGinnis SP, Hochella Jr MF, Rejeski D and Hull MS 2015. Nanotechnology in the real world: Redeveloping the nanomaterial consumer products inventory. *Beilstein journal of nanotechnology*, 6, 1769-1780.
- Xiu Z-m, Zhang Q-b, Puppala HL, Colvin VL and Alvarez PJ 2012. Negligible particle-specific antibacterial activity of silver nanoparticles. *Nano Letters*, 12, 4271-4275.
- Yohan D and Chithrani BD 2014. Applications of nanoparticles in nanomedicine. *Journal of biomedical nanotechnology*, 10, 2371-2392.
- Zia R, Riaz M, Farooq N, Qamar A and Anjum S 2018. Antibacterial activity of Ag and Cu nanoparticles synthesized by chemical reduction method: a comparative analysis. *Materials Research Express*, 5, 075012.